Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
AMGEN INC (AMGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS"
01/31/2023 8-K Quarterly results
Docs: "AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT",
"AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS",
"Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy"
08/04/2022 8-K Quarterly results
04/27/2022 8-K Quarterly results
Docs: "AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS",
"Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy"
02/07/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS"
08/03/2021 8-K Quarterly results
Docs: "AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS"
02/02/2021 8-K Quarterly results
10/28/2020 8-K Quarterly results
Docs: "AMGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS"
07/28/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "AMGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS"
01/30/2020 8-K Quarterly results
Docs: "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS"
10/29/2019 8-K Quarterly results
07/30/2019 8-K Quarterly results
04/30/2019 8-K Quarterly results
Docs: "AMGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS"
01/29/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "AMGEN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
07/26/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report July 26, 2018 AMGEN INC. Delaware 001-37702 95-3540776 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Registrant's telephone number, including area code 805-447-1000 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communi...",
"AMGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS"
04/24/2018 8-K Quarterly results
Docs: "FORM 8-K",
"AMGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS"
02/01/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report February 1, 2018 AMGEN INC. Delaware 001-37702 95-3540776 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Registrant's telephone number, including area code 805-447-1000 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement comm...",
"AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS Expects to Increase Investments in Growth, Including a New U.S. Manufacturing Plant Announces 2018 Guidance Additional $10 Billion of Share Repurchases Authorized"
10/25/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report October 25, 2017 AMGEN INC. Delaware 001-37702 95-3540776 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Registrant's telephone number, including area code 805-447-1000 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement comm...",
"AMGEN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS"
07/25/2017 8-K Form 8-K - Current report:
04/26/2017 8-K Form 8-K - Current report
02/02/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/27/2016 8-K Form 8-K - Current report
04/28/2016 8-K Quarterly results
Docs: "AMGEN'S FIRST QUARTER 2016 REVENUES INCREASED 10 PERCENT TO $5.5 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 17 PERCENT TO $2.90 First Quarter 2016 GAAP EPS Were $2.50 2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively"
01/28/2016 8-K Quarterly results
Docs: "AMGEN'S 2015 REVENUES INCREASED 8 PERCENT TO $21.7 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 19 PERCENT TO $10.38 2015 GAAP EPS Were $9.06 2016 Total Revenues and Adjusted EPS Guidance Increased to $22.0-$22.5 Billion and $10.60-$11.00, Respectively"
10/28/2015 8-K Quarterly results
Docs: "AMGEN'S THIRD QUARTER 2015 REVENUES INCREASED 14 PERCENT TO $5.7 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 18 PERCENT TO $2.72 Third Quarter 2015 GAAP EPS Increased 52 Percent to $2.44 2015 Total Revenues and Adjusted EPS Guidance Increased to $21.4-$21.6 Billion and $9.95-$10.10, Respectively Preliminary 2016 Total Revenues and Adjusted EPS Guidance of $21.7-$22.3 Billion and $10.35-$10.75, Respectively"
07/30/2015 8-K Quarterly results, Appointed a new director
Docs: "AMGEN'S SECOND QUARTER 2015 REVENUES INCREASED 4 PERCENT TO $5.4 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 8 PERCENT TO $2.57 Second Quarter 2015 GAAP EPS Increased 7 Percent to $2.15 2015 Total Revenues and Adjusted EPS Guidance Increased to $21.1-$21.4 Billion and $9.55-$9.80, Respectively",
"AMGEN ANNOUNCES APPOINTMENT OF FRED HASSAN TO BOARD OF DIRECTORS"
04/21/2015 8-K Quarterly results
Docs: "AMGEN'S FIRST QUARTER 2015 REVENUES INCREASED 11 PERCENT TO $5.0 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 33 PERCENT TO $2.48 First Quarter 2015 GAAP EPS Were $2.11 2015 Total Revenues and Adjusted EPS Guidance Increased to $20.9-$21.3 Billion and $9.35-$9.65, Respectively"
01/27/2015 8-K Quarterly results
Docs: "AMGEN'S 2014 REVENUES INCREASED 7 PERCENT TO $20.1 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 14 PERCENT TO $8.70 2014 GAAP EPS Were $6.70 2015 Revenues and Adjusted EPS Reaffirmed to be in the Range of $20.8-$21.3 Billion and $9.05-$9.40, Respectively"
10/27/2014 8-K Quarterly results
Docs: "AMGEN'S THIRD QUARTER 2014 REVENUES INCREASED 6 PERCENT TO $5.0 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 19 PERCENT TO $2.30 Third Quarter 2014 GAAP EPS Were $1.61 2014 Total Revenues and Adjusted EPS Guidance Increased to $19.8-$20.0 Billion and $8.45-$8.55, Respectively"
07/29/2014 8-K Quarterly results
Docs: "AMGEN'S SECOND QUARTER 2014 REVENUES INCREASED 11 PERCENT TO $5.2 BILLION AND ADJUSTED EARNINGS PER SHARE INCREASED 25 PERCENT TO $2.37 Second Quarter 2014 GAAP EPS Were $2.01 2014 Total Revenues and Adjusted EPS Guidance Increased to $19.5-$19.7 Billion and $8.20-$8.40, Respectively Reallocating Resources to Drive Growth"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy